US › Healthcare

Revelation Biosciences Inc (REVB)

US · Healthcare · Biotechnology

$0.95+3.26%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.3M

EPS

$-0.87

EPS estimate

$-0.83

EPS came in at -0.87 against a street estimate of -0.83 — a miss of 4.8%.

Key statistics

Market cap

$4.0M

P/E

0.0

Forward P/E

0.9

P/B

0.40

Book value

$2.58

EPS (TTM)

$27.03

52-week high

$7.60

52-week low

$0.88

50-day MA

$1.06

200-day MA

$1.69

Beta

-0.14

Analyst view

Analysts rate Revelation Biosciences Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $17.75.

Shareholding

Insiders

12.34%

Institutions

12.89%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	8.11%
Sabby Management LLC	2.50%
Geode Capital Management, LLC	1.08%
Citadel Advisors Llc	0.97%
Vanguard Fiduciary Trust Co	0.33%
XTX Topco Ltd	0.29%
UBS Group AG	0.10%
Tower Research Capital LLC	0.10%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Revelation Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.